Information Provided By:
Fly News Breaks for March 1, 2019
HZNP
Mar 1, 2019 | 09:22 EDT
JMP Securities analyst Donald Ellis raised his price target on Horizon Pharma to $38 from $26 after the company released top-line data for teprotumumab for the treatment of thyroid eye disease, stating that those data provide the pathway for a BLA submission in mid-2019. The analyst, who expects patients and physicians will be highly motivated to use Tepro immediately upon approval, now models a potential Tepro launch in 2020. Ellis keeps an Outperform rating on Horizon shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP